DLC1 Antibody

1. DLC1 is the predominant family member expressed in several normal tissues, and its expression is preferentially reduced in common cancers at these sites. PMID: 27174913
2. Fluctuation of reactive oxygen species inhibited migration through reducing the interaction between DLC1 and CAV-1. PMID: 28130753
3. IGF2 may exert its oncofunction, at least partly, through its parasitic miR-483 which suppressed DLC-1 in colorectal cancer cells. DLC-1 expression was decreased in colorectal cancer tissues and diminished through transient transfection with miR-483-3p. PMID: 27366946
4. The results of this study showed for the first time that CpGs of the DLC1-v1 alternative promoter is frequently hypermethylated in tumors of meningeal origin. PMID: 27614886
5. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1. PMID: 29114068
6. Study suggests a mechanism for EZH2-H3K27me3 epigenetic repression of DLC1 and multilayered regulation of DLC1/Rho/ROCK signaling by EZH2, and advocated the significant pro-metastatic role of EZH2 via repressing tumor and metastasis suppressors. PMID: 23826380
7. The results identify DLC1 as an activator of white and brown adipocyte differentiation, and provide a molecular link between PPARgamma and Rho pathways. PMID: 28358928
8. DLC-1 has a positive regulatory role in endothelial cell angiogenesis. PMID: 28408355
9. Subsequent studies have demonstrated that DLC-1 is generally expressed in normal human tissues as well as in rats, while it always exists inactivated or even lost in many human cancers, which characterizes DLC-1 as a potential tumor suppressor. [review] PMID: 27604574
10. Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7), and cadherin-6 (CDH6) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR-129-2 and members of the miR-200 family (miR-200a, miR-200b, and miR-429) as novel tumor suppressors and oncomiRs, respectively, in CC PMID: 27593557
11. it was demonstrated that the rs621554 polymorphism was correlated with DLC1 expression at the mRNA level. These results suggested that the rs621554 polymorphism is associated with breast cancer susceptibility and prognosis, and may serve as a biomarker for breast cancer development and progression. PMID: 26986853
12. curcumin down-regulates the expression of Sp1 to inhibit the expression of DNA methyltransferase 1, thus subsequently reducing hypermethylation of DLC1 promoter to induce DLC1 expression. PMID: 27830358
13. DLC-1 acts as a tumor suppressor gene in HCC by regulating the expression of RhoA/ROCK2/ moesin. PMID: 26846339
14. Low DLC-1 expression is associated with cancer. PMID: 26514520
15. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer. PMID: 26239822
16. No significant association of DLC1 SNPs with the patients' prognosis was found. PMID: 26095787
17. A phosphorylation-mediated molecular switch comprising DLC), TNS3, PTEN and PI3K controls the spatiotemporal activation of Rac1 and RhoA, thereby initiating directional cell migration induced by growth factors. PMID: 26166433
18. Data suggest BCL2-like 1 protein (BCL2L1) and deleted in liver cancer 1 protein (DLC1) as potential druggable targets for specific subsets of gastric cancer (GC) cases. PMID: 26401016
19. Low DLC1 expression is associated with cancer. PMID: 25743845
20. During early cell spreading, DLC1 is preferentially localized at the inner/mature adhesions whereas phosphorylated paxillin occupies the outer/nascent focal adhesions. In addition, DLC1 downregulates paxillin turnover PMID: 25448629
21. Cooperation of DLC1 and CDK6 affects breast cancer clinical outcome PMID: 25425654
22. Studies indicate that deleted in liver cancer-1 (DLC1) contributes to growth and migratory suppressive effects through GAP-dependent and GAP-independent mechanisms. PMID: 24338004
23. DLC-1 protein expression was negatively associated with both overall survival and with distant metastasis-free survival, but not with disease-free survival. PMID: 23510351
24. The CDK5 kinase phosphorylates four serines in DLC1 located N-terminal to the Rho-GAP domain. PMID: 25452387
25. Cox regression analysis determined that strong cytoplasmic and nuclear DLC1 expression was a favorable independent prognostic factor for all melanoma (HR, 0.61; 95% CI) and metastatic melanoma patients (HR, 0.42; 95% CI). PMID: 24557030
26. Evidence supports an anti-metastatic role for DLC1 in several human cancers.[Review] PMID: 24519699
27. DLC-1 inhibits cell growth and invasion in human colon cancer, functioning as a tumor-suppressor gene, possibly through the regulation of the Wnt/beta-catenin signaling pathway. PMID: 24604602
28. DLC-1 is negatively associated with nasopharyngeal carcinoma carcinogenesis, and promoter hypermethylation along with loss of heterozygosity, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma. PMID: 23908159
29. It is involved in proliferation and invasion of GBC cells and may serve as a potential therapeutic target. PMID: 24329682
30. Our data identify DLC1 as a locus for durable transgene expression that does not incur features of insertional oncogenesis, thus expanding options for developing ex vivo cell therapy mediated by site-specific integration methods. PMID: 24553346
31. DLC1 might act as a congenital heart disease-associated gene in addition to its role as a tumor suppressor in cancer. PMID: 24587289
32. The expression of DLC1 and PAI-1 were closely related with the metastasis and invasion of ovarian carcinoma, only the combination of DLC1 and PAI-1 could serve as an independent prognostic factor of ovarian carcinoma. PMID: 23988121
33. Study demonstrates that DLC1 expression positively regulates E-cadherin and suppresses highly metastatic PCA cell invasion by modulating Rho pathway. PMID: 23376848
34. Hypermethylation of DLC1 gene is associated with colon carcinogenesis. PMID: 23783552
35. Evaluation of clinical breast tumor samples revealed that reduced DLC1 expression was linked to elevated PTHLH expression and organ-specific metastasis to bone. PMID: 24590291
36. DLC-1 inhibits the proliferation, migration and tumorigenicity of human nasopharyngeal carcinoma cells. PMID: 23588806
37. DLC1 was ubiquitinated and degraded by cullin 4A-RING ubiquitin ligase (CRL4A) complex interaction with DDB1 and the FBXW5 substrate receptor. PMID: 24082123
38. DLC-1 methylation status was an independent prognostic factor for the overall survival rate of pancreatic ductal adenocarcinoma patients. PMID: 23681804
39. DLC1 plays a pivotal role in the development and progression of cutaneous squamous cell carcinoma. PMID: 23625658
40. analysis of DLC-1 epigenetic silencing in the mucosa-adenoma-carcinoma transformation process of colorectal cancer PMID: 23509688
41. study establishes a novel regulatory mechanism for DLC1 RhoGAP activity via dimerization induced by protein kinase A signalling PMID: 23511482
42. The abnormal expression of DLC1 and p-FAK might participate in the carcinogenesis, progression, and metastasis of breast cancer. PMID: 21868344
43. Downregulation of FAK gene expression or/and upregulation of DLC-1 gene expression can all inhibit the OVCAR-3 cell growth. PMID: 23079702
44. Several genes and biochemical activities collaborate with the inactivation of DLC1 to give rise to cell transformation in MEFs, and the identified genes are relevant to human tumors with low DLC1 expression. PMID: 23010077
45. The results showed that in breast cancer, DLC-1 gene expression was significantly lower than that in normal breast tissue and benign breast lesions. PMID: 22799310
46. Silencing FAK mRNA expression and DLC1 mRNA expression may markedly enhance caspase-3 and caspase-9 activities in ovarian cancer cells. PMID: 22760257
47. Aberrant DLC1 methylation and PIK3CA mutations may have important roles in extramammary Paget's disease pathogenesis. PMID: 22522847
48. a new mechanism through which DLC1 exerts its strong oncosuppressive function by positively influencing adherens junctions stability PMID: 22473989
49. complex formation between the DLC1 START domain and CAV-1 contributes to DLC1 tumor suppression via a RhoGAP-independent mechanism, and suggest that DLC1 inactivation probably contributes to cancer progression. PMID: 22693251
50. study provides evidence that MKL1/2 mediates cancerous transformation in DLC1-deficient hepatocellular and mammary carcinoma cells PMID: 22139079

Show More

Hide All

HGNC: 2897

OMIM: 604258

KEGG: hsa:10395

STRING: 9606.ENSP00000276297

UniGene: Hs.134296